Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.
机构：[1]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China[2]He'nan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[3]Cancer Hosptial, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China[4]Renjin Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China[5]Jiangsu Cancer Hospital, Nanjing, China[6]Beijing Cancer Hospital and Institute, Beijing, China[7]Department of Thoracic Oncology, State Key Laboratory of Biotherapy, Huaxi Hospital, Sichuan University, Chengdu, China四川大学华西医院[8]Department of Radiation Oncology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[9]Fourth Hospital, Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[10]University of Texas M. D. Anderson Cancer Center, Houston, TX
第一作者机构：[1]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
推荐引用方式(GB/T 7714)：
Yu Jinming,Meng Xue,Wang Jian Hua,et al.Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.[J].JOURNAL OF CLINICAL ONCOLOGY.2012,30(15):doi:10.1200/jco.2012.30.15_suppl.4073.
APA：
Yu, Jinming,Meng, Xue,Wang, Jian Hua,Sun, Xindong,Wang, Lv Hua...&Liao, Zhongxing X..(2012).Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study..JOURNAL OF CLINICAL ONCOLOGY,30,(15)
MLA：
Yu, Jinming,et al."Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.".JOURNAL OF CLINICAL ONCOLOGY 30..15(2012)
医学